Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
4.080
+0.630 (18.26%)
Aug 4, 2026, 11:37 AM EDT - Market open
Ernexa Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 9.18 | 1.88 | 1.73 | 7.58 | 11.45 | 16.99 |
Cash & Short-Term Investments | 9.18 | 1.88 | 1.73 | 7.58 | 11.45 | 16.99 |
Cash Growth | 378.47% | 8.96% | -77.18% | -33.82% | -32.61% | 942.02% |
Other Receivables | 0.1 | 0.85 | 0.44 | 0.43 | 0.95 | 0.68 |
Total Trade Receivables | 0.1 | 0.85 | 0.44 | 0.43 | 0.95 | 0.68 |
Other Current Assets | 0.72 | 0.4 | 0.19 | 1.6 | 1.28 | 1.1 |
Total Current Assets | 10 | 3.13 | 2.35 | 9.6 | 13.68 | 18.77 |
Net Property, Plant & Equipment | 0.44 | 0.55 | 0.76 | 33.27 | 1.27 | 3.24 |
Goodwill | - | 2.04 | 2.04 | 2.04 | 2.04 | 2.04 |
Long-Term Investments | - | - | - | - | 0.06 | 1 |
Other Long-Term Assets | 0.11 | 0.11 | 0.12 | 4.22 | 5.23 | 6.48 |
Total Assets | 10.54 | 5.83 | 5.27 | 49.13 | 22.28 | 31.53 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.3 | 1.13 | 1.72 | 1.07 | 1.62 | 1.76 |
Accrued Expenses | 1.48 | 0.9 | 1.01 | 1.89 | 3.63 | 1.25 |
Current Portion of Leases | 0.16 | 0.21 | 0.21 | 2.22 | 0.3 | 0.43 |
Unearned Revenue | - | - | - | 0.19 | - | - |
Other Current Liabilities | 0.51 | 0.88 | 0 | 1.31 | 2.11 | 0.25 |
Total Current Liabilities | 3.46 | 3.11 | 2.94 | 6.57 | 7.65 | 3.68 |
Long-Term Debt | - | - | - | 6.77 | - | - |
Long-Term Leases | 0.23 | 0.28 | 0.48 | 32.85 | 0.89 | 2.3 |
Other Long-Term Liabilities | 0 | 0.04 | 0.15 | 0.59 | 1.63 | 0.05 |
Total Long-Term Liabilities | 0.23 | 0.32 | 0.63 | 40.22 | 2.52 | 2.35 |
Total Liabilities | 3.68 | 3.43 | 3.57 | 46.9 | 10.17 | 6.02 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.01 | 0.04 | 0.02 | 0.03 | 0.03 | 0.01 |
Additional Paid-in Capital | 257.99 | 248 | 233.22 | 189.19 | 177.38 | 166.19 |
Retained Earnings | -251.14 | -245.64 | -231.54 | -186.98 | -165.3 | -140.7 |
Shareholders' Equity | 6.86 | 2.4 | 1.7 | 2.23 | 12.11 | 25.5 |
Total Liabilities & Equity | 10.54 | 5.83 | 5.27 | 49.13 | 22.28 | 31.53 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.39 | 0.49 | 0.68 | 41.84 | 1.18 | 2.72 |
Net Cash (Debt) | 8.79 | 1.39 | 1.05 | -34.27 | 10.26 | 14.26 |
Net Cash Growth | - | 33.40% | - | - | -28.03% | - |
Net Cash Per Share | 21.20 | 5.53 | 28.71 | -2420.06 | - | - |
Book Value | 6.86 | 2.4 | 1.7 | 2.23 | 12.11 | 25.5 |
Book Value Per Share | 16.54 | 9.52 | 46.73 | 157.70 | - | - |
Tangible Book Value | 6.86 | 0.36 | -0.34 | 0.19 | 10.06 | 23.46 |
Tangible Book Value Per Share | 16.54 | 1.42 | -9.42 | 13.35 | - | - |